Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GLPG
stocks logo

GLPG

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
70.53M
-9.43%
--
--
66.64M
+11.35%
--
--
70.43M
-6.71%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Galapagos NV (GLPG) for FY2025, with the revenue forecasts being adjusted by -0.19% over the past three months. During the same period, the stock price has changed by 26.38%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.19%
In Past 3 Month
Stock Price
Go Up
up Image
+26.38%
In Past 3 Month
4 Analyst Rating
down Image0
Wall Street analysts forecast GLPG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLPG is 24.33 USD with a low forecast of 22.00 USD and a high forecast of 27.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
1 Sell
Hold
down Image0
Current: 31.140
sliders
Low
22.00
Averages
24.33
High
27.00
down Image0
Current: 31.140
sliders
Low
22.00
Averages
24.33
High
27.00
Morgan Stanley
Judah Frommer
Hold
to
Sell
Downgrades
$31 → $22
2025-02-14
Reason
Morgan Stanley
Judah Frommer
Price Target
$31 → $22
2025-02-14
Downgrades
Hold
to
Sell
Reason
Morgan Stanley downgraded Galapagos to Underweight from Equal Weight with a price target of $22, down from $33.
Barclays
Emily Field
Hold
to
Sell
Downgrades
n/a
2025-01-23
Reason
Barclays
Emily Field
Price Target
n/a
2025-01-23
Downgrades
Hold
to
Sell
Reason
RBC Capital
Brian Abrahams
Hold
Maintains
$32 → $30
2024-11-01
Reason
RBC Capital
Brian Abrahams
Price Target
$32 → $30
2024-11-01
Maintains
Hold
Reason
Leerink Partners
Faisal Khurshid
Hold
Initiates
$24
2024-09-09
Reason
Leerink Partners
Faisal Khurshid
Price Target
$24
2024-09-09
Initiates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Galapagos NV (GLPG.O) is -23.12, compared to its 5-year average forward P/E of -6.88. For a more detailed relative valuation and DCF analysis to assess Galapagos NV 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.88
Current PE
-23.12
Overvalued PE
92.21
Undervalued PE
-105.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
9.42
Current EV/EBITDA
8.69
Overvalued EV/EBITDA
18.82
Undervalued EV/EBITDA
0.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
7.60
Current PS
6.43
Overvalued PS
10.20
Undervalued PS
5.01

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 32620.27% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

GLPG News & Events

Events Timeline

(ET)
2025-06-23
05:11:08
Galapagos CFO Thad Huston to depart, Aaron Cox to succeed
select
2025-06-18 (ET)
2025-06-18
16:07:16
Galapagos presents new data from ATALANTA-1 trial
select
2025-06-12 (ET)
2025-06-12
16:07:21
Galapagos to present new data from ATALANTA-1 trial
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
06-26NASDAQ.COM
Galapagos Reaches Analyst Target Price

  • Current Stock Performance: Galapagos NV's shares have surpassed the average analyst 12-month target price of $27.70, trading at $27.71, prompting analysts to consider either downgrading their valuation or raising their target prices based on the company's performance.

  • Analyst Target Variability: There is a range of analyst targets for Galapagos NV, with one as low as $22.00 and another as high as $40.50, indicating differing opinions on the stock's future value and suggesting investors should evaluate whether to hold or sell their shares.

Preview
9.0
06-19Newsfilter
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

  • Study Results: The ATALANTA-1 Phase 1/2 study of GLPG5101, a CAR-T cell therapy for relapsed/refractory indolent non-Hodgkin lymphoma, showed a 97% complete response rate and 100% minimal residual disease negativity in evaluable patients, with durable CAR-T cell persistence and a favorable safety profile.

  • Manufacturing Advancements: Galapagos' decentralized manufacturing platform enabled 93% of patients to receive fresh CAR-T cells within seven days without the need for cytotoxic bridging therapy, highlighting significant improvements in treatment delivery for patients with limited options.

Preview
9.0
06-13NASDAQ.COM
Galapagos Unveils Low-Toxicity CAR-T Data From ATALANTA-1 In Relapsed Non-Hodgkin's Lymphoma

  • Clinical Data Presentation: Galapagos NV will present new clinical data from its ATALANTA-1 Phase 1/2 study of GLPG5101 at the EHA Congress, highlighting low rates of high-grade toxicities and successful rapid delivery of CAR-T cells to patients with relapsed/refractory non-Hodgkin's lymphoma.

  • Decentralized Manufacturing Impact: The study indicates that a decentralized manufacturing approach may enhance access to CAR-T therapy by reducing patient attrition and manufacturing times, potentially benefiting more patients who might otherwise be excluded from treatment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Galapagos NV (GLPG) stock price today?

The current price of GLPG is 31.14 USD — it has increased 1.57 % in the last trading day.

arrow icon

What is Galapagos NV (GLPG)'s business?

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

arrow icon

What is the price predicton of GLPG Stock?

Wall Street analysts forecast GLPG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLPG is 24.33 USD with a low forecast of 22.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Galapagos NV (GLPG)'s revenue for the last quarter?

Galapagos NV revenue for the last quarter amounts to 74.98M USD, increased 4.40 % YoY.

arrow icon

What is Galapagos NV (GLPG)'s earnings per share (EPS) for the last quarter?

Galapagos NV. EPS for the last quarter amounts to -2.33 USD, decreased -270.07 % YoY.

arrow icon

What changes have occurred in the market's expectations for Galapagos NV (GLPG)'s fundamentals?

The market is revising Downward the revenue expectations for Galapagos NV (GLPG) for FY2025, with the revenue forecasts being adjusted by -0.19% over the past three months. During the same period, the stock price has changed by 26.38%.
arrow icon

How many employees does Galapagos NV (GLPG). have?

Galapagos NV (GLPG) has 704 emplpoyees as of July 19 2025.

arrow icon

What is Galapagos NV (GLPG) market cap?

Today GLPG has the market capitalization of 2.05B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free